The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Abstract
Standard protocols for the generation of adenoassociated virus type 2 (AAV-2)-based vectors for human gene therapy applications require cotransfection of cells with a recombinant AAV (rAAV) vector plasmid and a packaging plasmid that provides the AAV rep and cap genes. The transfected cells must also be overinfected with a helper virus, e.g., adenovirus (Ad), which delivers multiple helper functions necessary for rAAV production. Therefore, rAAV stocks produced using these protocols are contaminated with helper adenovirus. The generation of a novel packaging/helper plasmid, pDG, containing all AAV and Ad functions required for amplification and packaging of AAV vector plasmids, is described here. Cotransfection of cells with pDG and an AAV vector plasmid was sufficient for production of infectious rAAV, resulting in helper virus-free rAAV stocks. The rAAV titers obtained using pDG as packaging plasmid were up to 10-fold higher than those achieved using conventional protocols for rAAV production. Replacement of the AAV-2 p5 promoter by an MMTV-LTR promoter in pDG led to reduced expression of Rep78/68; however, expression of the VP proteins was significantly increased compared with VP levels from standard packaging plasmids. Immunofluorescence analyses showed that the strong accumulation of VP proteins in pDG-transfected cells resulted in enhanced AAV capsid assembly, which is limiting for efficient rAAV production. Furthermore, using a monoclonal antibody highly specific for AAV-2 capsids (A20), an rAAV affinity purification procedure protocol was established. The application of the tools described here led to a significant improvement in recombinant AAV vector production and purification. Two novel tools allowing a simplified and more efficient generation and purification of adenoassociated virus type 2 (AAV-2)-derived vectors are described here. First, the generation of an AAV/adenovirus hybrid plasmid, pDG, which contains all packaging and helper functions required for production of recombinant AAV (rAAV), is reported. Cotransfection of cells with pDG and an AAV vector plasmid led to production of several hundred infectious rAAV particles per transfected cell. Using pDG as a helper plasmid, generation of rAAV was no longer dependent on overinfection of the cells with adenovirus, resulting in helper virus-free rAAV stocks. Second, an rAAV affinity purification procedure based on the monoclonal antibody A20, which specifically recognizes assembled AAV-2 capsids, is described. Detailed analyses of rAAV production using the new packaging and purification tools in comparison with standard protocols are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-efficiency transformation of mammalian cells by plasmid DNA.
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,373
Selective extraction of polyoma DNA from infected mouse cell cultures
Hirt, B. (1967) · Journal of Molecular Biology · doi:10.1016/0022-2836(67)90307-5 · Cited by 5,146
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Current Protocols in Human Genetics
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142905 · Cited by 987
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
Samulski, R. J., Zhu, X., Xiao, X., Brook, J. D., Housman, D. E., Epstein, N., & Hunter, L. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04964.x · Cited by 784
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
Cited by
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Production and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
DNA Transposons: Nature and Applications in Genomics
Munoz-Lopez, M., & Garcia-Perez, J. (2010) · Current Genomics · doi:10.2174/138920210790886871 · Cited by 447
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Self-citationEisch, A. J., Bolaños, C. A., de Wit, J., Simonak, R. D., Pudiak, C. M., Barrot, M., Verhaagen, J., & Nestler, E. J. (2003) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.003 · Cited by 420
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Self-citationHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
Opie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364
Martin, K. R. G., Quigley, H. A., Zack, D. J., Levkovitch-Verbin, H., Kielczewski, J., Valenta, D., Baumrind, L., Pease, M. E., Klein, R. L., & Hauswirth, W. W. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1332 · Cited by 362
Grimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Self-citationGrimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344
Self-citationGene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 340
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 334
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
“other Ad helper genes and the AAV1 rep and cap genes (23).”
BackgroundGrieger, J. C., Soltys, S. M., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.187 · Cited by 325
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Hadaczek, P., Yamashita, Y., Mirek, H., Tamas, L., Bohn, M. C., Noble, C., Park, J. W., & Bankiewicz, K. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.018 · Cited by 312
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Auricchio, A., Hildinger, M., O'Connor, E., Gao, G.-P., & Wilson, J. M. (2001) · Human Gene Therapy · doi:10.1089/104303401450988 · Cited by 297
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Sonntag, F., Bleker, S., Leuchs, B., Fischer, R., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.01056-06 · Cited by 280
Self-citationWobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273
Self-citationRodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
Felberbaum, R. S. (2015) · Biotechnology Journal · doi:10.1002/biot.201400438 · Cited by 264
CRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 260
Self-citationSumoylation inhibits α-synuclein aggregation and toxicity
Krumova, P., Meulmeester, E., Garrido, M., Tirard, M., Hsiao, H.-H., Bossis, G., Urlaub, H., Zweckstetter, M., Kügler, S., Melchior, F., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010117 · Cited by 254
TrkB Gene Transfer Protects Retinal Ganglion Cells from Axotomy-Induced Death In Vivo
Cheng, L., Sapieha, P., Kittlerová, P., Hauswirth, W. W., & Di Polo, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-03977.2002 · Cited by 254
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Warrington, K. H., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., & Muzyczka, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6595-6609.2004 · Cited by 205
Klein, R. L., Dayton, R. D., Leidenheimer, N. J., Jansen, K., Golde, T. E., & Zweig, R. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.008 · Cited by 200
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Kronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198
Self-citationGrimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195
Self-citationPharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Gene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149
Davidsson, M., Wang, G., Aldrin-Kirk, P., Cardoso, T., Nolbrant, S., Hartnor, M., Mudannayake, J., Parmar, M., & Björklund, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910061116 · Cited by 142
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material
Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.223 · Cited by 131
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131
Advances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
Favre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
Griffey, M., Macauley, S. L., Ogilvie, J. M., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.018 · Cited by 115
Gene targeting in vivo by adeno‐associated virus vectors
Miller, D. G., Wang, P.-R., Petek, L. M., Hirata, R. K., Sands, M. S., & Russell, D. W. (2006) · Nature Biotechnology · doi:10.1038/nbt1231 · Cited by 105
Zentilin, L., Marcello, A., & Giacca, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12279-12287.2001 · Cited by 101
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain
Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., & During, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8446-8454.2002 · Cited by 87
Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors
Jungmann, A., Leuchs, B., Rommelaere, J., Katus, H. A., & Müller, O. J. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.192 · Cited by 79
Schnödt, M., & Büning, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.188 · Cited by 77
A macrophage-hepatocyte glucocorticoid receptor axis coordinates fasting ketogenesis
Loft, A., Schmidt, S. F., Caratti, G., Stifel, U., Havelund, J., Sekar, R., Kwon, Y., Sulaj, A., Chow, K. K., Alfaro, A. J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.004 · Cited by 76
Development of AAV serotype-specific ELISAs using novel monoclonal antibodies
Kuck, D., Kern, A., & Kleinschmidt, J. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.10.005 · Cited by 74
Self-citationBleker, S., Pawlita, M., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.810-820.2006 · Cited by 75
Self-citationAdeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Hackett, N. R., Redmond, D. E., Sondhi, D., Giannaris, E. L., Vassallo, E., Stratton, J., Qiu, J., Kaminsky, S. M., Lesser, M. L., Fisch, G. S., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1484 · Cited by 57
Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9
Tomono, T., Hirai, Y., Okada, H., Miyagawa, Y., Adachi, K., Sakamoto, S., Kawano, Y., Chono, H., Mineno, J., Ishii, A., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.015 · Cited by 55
François, A., Bouzelha, M., Lecomte, E., Broucque, F., Penaud-Budloo, M., Adjali, O., Moullier, P., Blouin, V., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.004 · Cited by 50
Characterization of AAV vectors: a review of analytical techniques and critical quality attributes
Kontogiannis, T., Braybrook, J., McElroy, C., Foy, C., Whale, A. S., Quaglia, M., & Smales, C. M. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101309 · Cited by 57
Nony, P., Chadeuf, G., Tessier, J., Moullier, P., & Salvetti, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.776-781.2003 · Cited by 51
Otukonyong, E. E., Dube, M. G., Torto, R., Kalra, P. S., & Kalra, S. P. (2005) · Peptides · doi:10.1016/j.peptides.2005.04.015 · Cited by 46
PPP2R5C couples hepatic glucose and lipid homeostasis
Cheng, Y.-S., Seibert, O., Klöting, N., Dietrich, A., Straßburger, K., Fernández-Veledo, S., Vendrell, J. J., Zorzano, A., Blüher, M., Herzig, S., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005561 · Cited by 43
Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction
Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., & Giacca, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503607112 · Cited by 39
Gene therapy for achromatopsia
Michalakis, S., Schön, C., Becirovic, E., & Biel, M. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2944 · Cited by 41
“(iv) Helper virus‐free protocols have been established for the production of rAAV particles in eukaryotic cells or in insect cells.(31,32) In these protocols, the cis plasmid with the desired gene expression cassette, the rep and cap expressing plasmids and the helper plasmid containing the adenoviral helper genes E1A…”
MethodDNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39
Vector characterization methods for quality control testing of recombinant adeno-associated viruses
Wright, J. F., & Zelenaia, O. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_11 · Cited by 34
Hendrie, P. C., Hirata, R. K., & Russell, D. W. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13136-13145.2003 · Cited by 33
Hüser, D., Weger, S., & Heilbronn, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4881-4887.2003 · Cited by 29
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
Chaanine, A. H., Nonnenmacher, M., Kohlbrenner, E., Jin, D., Kovacic, J. C., Akar, F. G., Hajjar, R. J., & Weber, T. (2014) · Gene Therapy · doi:10.1038/gt.2014.7 · Cited by 25
Koch (2014) · doi:10.1074/jbc.m113.504860 · Cited by 25
AAV Production Using Baculovirus Expression Vector System
Sandro, Q., Relizani, K., & Benchaouir, R. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9065-8_5 · Cited by 24
Landeck, N., Strathearn, K. E., Ysselstein, D., Buck, K., Dutta, S., Banerjee, S., Lv, Z., Hulleman, J. D., Hindupur, J., Lin, L.-K., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00380-w · Cited by 19
de Oliveira, A. P., & Fraefel, C. (2010) · The Open Virology Journal · doi:10.2174/1874357901004030109 · Cited by 3
Metadata
- Authors
- Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-12-10
- Volume
- 9
- Issue
- 18
- Pages
- 2745-2760
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2059108053
- Cited by
- 696
- References
- 53
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.